Support Burnet’s COVID-19 emergency response
COVID-19 represents an unprecedented health, social and economic challenge in Australia and around the world. Support Burnet’s COVID-19 emergency response today.
COVID-19 represents an unprecedented health, social and economic challenge in Australia and around the world. Support Burnet’s COVID-19 emergency response today.
Kate Cherry has had a long standing interest in understanding HIV-SN, a common problem affecting the patients she sees living with HIV infection which causes chronic, disabling neuropathic pain and is very difficult to treat. It negatively impacts on patients' quality of life, mobility and ability to work.
Kate has validated a simple screening tool for detecting patients with HIV-SN in the clinic and has trained colleagues from other centres in the use of this tool so that identical methods can be used to understand the epidemiology of HIV-SN in multiple clinics.
To date, we have examined the rates and risk factors for HIV-SN in populations seeking HIV care in Australia, the USA, South Africa, Indonesia and Malaysia. We have demonstrated that very simple things (such as patient age and height) can be used to predict which patients are at a higher risk, identifying a population to whom preventative strategies can be targeted at no extra cost.
In collaboration with colleagues in Perth (P Price), we have undertaken initial genetic studies suggesting that inflammation may be important in the development of HIV-SN, with possible implications for new treatments for neuropathy in the future.
We are now expanding this work with colleagues in South Africa (P Kamerman) and have formed an international consortium (Australia, South Africa and UK) that hopes to undertake more detailed genetic studies of HIV-SN risk in the future.
We have shown that HIV-SN is very common, affecting around 30 percent of patients living with HIV, even when patients have never been treated with potentially neurotoxic medications. Rates are >40 percent in cohorts where these drugs have been used.
We find patient age, height, ethnicity and choice of antiretroviral drugs (but no hepatitis C - previously suggested as an HIV-SN risk factor) are associated with HIV-SN risk. In addition, genes associated with inflammation may modulate the individual’s risk.
Patricia Price, University of Western Australia (with UWA PhD candidate Constance Chew)
Peter Kamerman, University of Witwatersrand, South Africa (with UW PhD candidate Antonia Wadley)
Andrew Rice and Dave Bennet, London Pain Consortium
Justin McArthur, Johns Hopkins University, USA
Bruce Brew, University of NSW
Evy Yunihastuti, Jakarta, Indonesia
Adeeba Kamarulzaman, Kuala Lumpur, Malaysia
For any general enquiries relating to this project, please contact:
Burnet Staff Physician and Clinical Epidemiologist
To achieve better health for vulnerable communities in Australia and internationally by accelerating the translation of research, discovery and evidence into sustainable health solutions.
85 Commercial Road, Melbourne
VIC, 3004, Australia
Receive updates and IMPACT magazine.
Copyright © 2020 Burnet Institute. ABN: 49 007 349 984
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung and Wurundjeri people and we offer our respects to the elders past and present.
We recognise and respect the cultural heritage of this land.
